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Platelet-derived growth factor receptor b (PDGFRb) immunohistochemistry highlights
activated bone marrow stroma and is potentially predictive for fibrosis progression in
prefibrotic myeloproliferative neoplasia
Aims: Myelofibrosis is the result of aberrant stromal
activity which is determined routinely by reticulin
staining in bone marrow biopsies. As matrix fibres
are the product of activated fibroblasts, we analysed
fibre accumulation compared to stromal cell activity
during myelofibrosis progression using the fibroblast
activation marker platelet-derived growth factor
receptor b (PDGFRb) by immunohistochemistry.
Methods and results: Initial and follow-up bone mar-
row biopsies from 84 patients with myeloproliferative
neoplasia, including 55 cases with primary myelofi-
brosis, were evaluated from five haematopathology
centres. The stromal mass was measured by conven-
tional reticulin staining [myelofibrosis (MF) grade,
0–3] and PDGFRb-positive cells using a novel
PDGFRb scoring system (0–3). Results were corre-
lated for prediction of progression. The MF grade and
the PDGFRb score showed excellent correlation
(Spearman’s r = 0.83, P < 0.0001). Elevated PDGFRb
scores (higher than MF-grade) predicted myelofibrosis
progression in total with 43% sensitivity and 57%
specificity, and short-term (within 1 year) progression
with 82% sensitivity and 53% specificity. Progression
of prefibrotic disease to manifest myelofibrosis could
be forecast with 90% sensitivity and 75% specificity.
Conclusion: PDGFRb highlights stromal cell activa-
tion in marrow fibrosis, which is closely related to
matrix accumulation, indicating a direct clinical
impact especially in prefibrotic myeloproliferative dis-
orders.
Keywords: bone marrow, immunohistochemistry, platelet-derived growth factor receptor, primary myelofibrosis
Introduction
Myelofibrosis (MF) is the result of bone marrow stro-
mal cell activation occurring frequently in different
pathological conditions of the bone marrow.1–3 Accu-
mulation of the non-haematopoetic stroma consists of
both mesenchymal cellular components and intersti-
tial matrix, the latter composed predominantly of reti-
culin and collagen fibres.4,5 While the matrix fibre
deposition is determined routinely using reticulin
silver staining, much less attention is paid to the
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activation and proliferation of stromal cells. Fibro-
blasts responsible for the production of reticulin and
collagen fibres are not prominent in the normal bone
marrow4 and become numerous only upon stimula-
tion from the microenvironment.6,7 Several growth
factors, including megakaryocyte-derived basic fibro-
blastic growth factor (bFGF), transforming growth
factor (TGF)-b and platelet-derived growth factor
(PDGF), have been proposed to be the most important
inducers of fibroblast activation and fibre production
during the process of MF.8–11 Growth factors act by
specific triggering of the appropriate surface mem-
brane receptor pathways in the target cells.12,13 Pre-
vious studies have demonstrated that platelet-derived
growth factor receptors (PDGFR) show a differential
expression in the mesenchymal cell types of the bone
marrow and that the PDGFRb subunit is expressed
predominantly by activated fibroblasts in a cell type-
specific manner.6,12 Moreover, the extent of the
PDGFRb subunit demonstrated by immunohistochem-
istry (IHC) in bone marrow biopsy samples correlated
closely with the degree of matrix fibre accumulation
in MF.6 Notably, despite the strong correlation
between stromal cell activation and fibre accumula-
tion, fibroblast-related PDGFRb immunostaining
proved to be more prominent than the amount of
fibre accumulation in selected cases, suggesting a pro-
gressive potential of the stromal changes.
As PDGFRb appeared to be useful for the character-
ization of MF, the question was raised as to whether
the histological demonstration of activated fibroblasts
might principally indicate ongoing fibrosis, and thus
predict the course of MF progression. For this pur-
pose, a statistically significant number of sequential
bone marrow samples from the same patients need to
be evaluated, which are rarely provided. To evaluate
the utility of PDGFRb assessment by IHC and to
address its predictive potential in the long- and short-
term follow-up of primary myelofibrosis (PMF), a ret-
rospective multicentre study was initiated with the
participation of the members of the European Bone
Marrow Working Group. Initial and follow-up bone
marrow biopsy samples featuring different degrees of
MF were collected and evaluated for the fibroblast
activation marker PDGFRb using IHC and for the
fibre products highlighted by conventional reticulin
silver staining.
Materials and methods
Archival cases of 84 patients having had multiple
bone marrow examinations were collected by the
following participants: the Institute of Pathology at
the University Hospital Basel, Switzerland, the Rad-
boud University Nijmegen Medical Center, the Neth-
erlands, the Charite – University Medicine, Berlin,
Germany, the Laboratory of Tumor Pathology and
Molecular Diagnostics, Szeged, Hungary and the
Department of Pathology, University of Debrecen,
Hungary. Clinical and histological diagnoses and
basic patient data, including time of sampling, were
provided in an anonymized fashion. Detailed evalua-
tion of clinical and laboratory parameters was not
the aim of this study. Histopathological evaluation of
the slides was performed in accordance with the gen-
eral ethical regulations and with the approval of the
local ethical committees.
A total of 193 biopsy samples were obtained from
84 patients, including 55 PMF, eight essential
thrombocythaemia (ET), five polycythaemia vera
(PV), three chronic myeloid leukaemia (CML) and a
further three unclassifiable myeloproliferative neopla-
sias (MPN-U) and four overlapping MPN/myelodys-
plastic neoplasias (MDS). Myeloproliferative neoplasia
was associated with other bone marrow disorders or
conditions in six additional cases [lymphoproliferative
disorders, granulocyte–macrophage colony-stimulat-
ing factor (GM-CSF) therapy]. Usually two serial sam-
ples per case represented the course of the disease,
although for some cases three or more biopsies were
provided. The mean follow-up time was 34.4 months
(range = 2–151 months).
Within the study collection, PMF represented the
largest homogeneous disease group which could be
evaluated separately. Altogether, 126 initial and fol-
low-up biopsy samples from 55 PMF cases were anal-
ysed. The mean follow-up time was 30.1 months
(range = 2–143 months).
Detailed evaluation of stromal fibrosis using reticu-
lin silver staining and cellular PDGFRb expression fol-
lowing immunohistochemistry was performed at the
Department of Pathology, University of Debrecen,
Hungary. To specifically demonstrate PDGFRb-posi-
tive bone marrow cells, samples were incubated with
the anti-PDGFRb (ab-32570; Abcam, Cambridge, UK)
primary monoclonal antibody at a dilution of 1:100,
as described previously.6 Antibody binding was visu-
alized by the Dako EnVision FLEX/HRP and FLEX
DAB3 Chromogen detection system (Dako, Glostrup,
Denmark). The PDGFRb score was determined by
microscopic analysis according to a previously pro-
posed scoring system.6 The reticulin grade staining
was determined following G€om€ori’s reticulin staining
according to the European Consensus on grading
bone marrow fibrosis.5 To enhance reproducibility,
© 2015 John Wiley & Sons Ltd, Histopathology
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both stainings were evaluated in a blinded fashion
using the same criteria by two histologists indepen-
dently, and the results were compared. In case of dis-
agreement a consensus decision was achieved.
Statistical evaluation and graphs were made using
the GraphPad Prism software. Mean and standard
deviations were calculated for each group and
analysed with Student’s t-test. P-values <0.05
were considered statistically significant. Correlations
between data sets were obtained using linear regres-
sion analysis.
Results
R E T I C U L I N G R A D E A N D P D G F R b E X P R E S S I O N
C O R R E L A T E S T R O N G L Y I N M F I R R E S P E C T I V E O F
T H E T Y P E O F M P N
IHC preparations were generally of high quality and
optimal for microscopic analysis, irrespective of the
admission site, and semiquantitative microscopic eval-
uations were performed in all 193 samples from 84
patients using the previously established scoring sys-
tem (Figure 1). The relation of MF grade and
PDGFRb score for each sample was assessed and a
strong correlation was found between the amount of
accumulated fibres (MF grade) and the activated stro-
mal cell component expressed by the PDGFRb score
(Spearman’s r = 0.83, P < 0.0001) (Figure 2A). Eval-
uation of the 126 samples from 55 cases with PMF
diagnosis gave similar results (Spearman’s r = 0.86,
P < 0.0001) (Figure 2B). This correlation was statis-
tically constant through all grades of PMF when the
initial (Spearman’s r = 0.84, P < 0.0001) and the
follow-up samples (Spearman’s r = 0.82, P < 0.0001)
were evaluated separately.
P R E D I C T I O N O F P R O G R E S S I O N I N A L L M F
S A M P L E S U S I N G T H E P D G F R b S C O R I N G S Y S T E M
At the time of diagnosis, 14 of 84 cases showed MF-
0, 30 cases MF-1, 21 cases MF-2 and 19 cases MF-3,
while the PDGFRb score was PDGFRb-0 in four cases,
PDGFRb-1 in 31 cases, PDGFRb-2 in 24 cases and
PDGFRb-3 in 25 cases. The PDGFRb score was
higher than the MF grade in 29 of 84 cases (34.5%),
equal to the MF grade in 51 of 84 cases (60.7%) and
lower than the MF grade in only four of 84 cases
(4.7%). Thirty-four of the total 84 cases showed pro-
gression in MF grade during the whole follow-up per-
iod, while 40 cases did not show any change. The
remaining 10 cases showed regression/reduction of
fibrosis. Of these 10 cases, in three cases anti-MF
medication was applied, while in a further three cases
stem cell transplantation was performed; in the four
remaining cases no clinical data were available. Rep-
resentative morphological changes related to fibrosis
progression are presented in Figure 3. We evaluated
the relation of initial PDGFRb scores with MF pro-
gression defined by the increase of MF grade during
the follow-up period. Cases with no change or a
decrease in fibre content during follow-up were
A
C
B
D
Figure 1. 5Platelet-derived
growth factor receptor b
(PDGFRb) immunohistoche-
mistry in bone marrow
trephine biopsies highlights
myelofibrosis-related stromal
cell activation. Positive
staining represents stromal
fibroblasts in different amounts
in parallel with reticulin fibre
accumulation. A four-grade
(0–3) scoring system was
uniformly applicable for all
initial and follow-up samples
collected in our collaborative
study (A = score 0, B = score
1, C = score 2, D = score 3).
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considered as non-progressive. Nineteen of the 84
cases (22.6%) had already presented with fully devel-
oped myelofibrosis (MF-3) at the time of the initial
diagnosis, and thus further progression was no longer
possible. The statistical analysis was performed after
their exclusion. Figure 4A shows the outcome of MF
in cases with higher (n = 28), equal (n = 34) and
lower (n = 3) PDGFRb scores compared to MF grade
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Figure 2. Graphical presentation of the correlation between myelofibrosis (MF) grades and platelet-derived growth factor receptor b
(PDGFRb) scores of the same bone marrow samples. The reticulin grade and the PDGFRb immunohistochemistry (IHC) score were deter-
mined and matched in the 193 samples from all the 84 cases collected within this study (A) and in the 126 samples from the 55 primary
myelofibrosis (PMF) cases (B).
Figure 3. Examples of the microscopic changes in the successive bone marrow samples from a case with progressive primary myelofibrosis
(PMF). Hypercellularity [haematoxylin and eosin (H&E) staining], no fibre accumulation (MF-0, reticulin staining) and mild stromal cell acti-
vation [platelet-derived growth factor receptor b (PDGFRb) score-1, immunohistochemistry] was visible in the initial biopsy sample (upper
row). The same cellularity accompanied with mild increase in fibrosis (MF-1) and with extended stromal cell activation (PDGFRb score-2)
indicated progression in the follow-up sample obtained 7 months later (lower row).
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during the whole follow-up period. Using the log-rank
test there was no significant difference in the proba-
bility of fibrosis progression in the different PDGFRb
subgroups (P = 0.4547). To evaluate the short-term
effect of stromal cell PDGFRb expression, the same
analysis was performed for cases having follow-up
samples within the initial 12 months after diagnosis
(26 cases). Eleven of the 26 (42.31%) matched short-
term sample pairs showed progression, while in 15
cases (57.69%) there was no progression. The log-
rank test did not show any significant difference in
the probability of fibrosis progression in these short-
term follow-up series (P = 0.7398) (Figure 4B).
PDGFRb scores higher than the MF grade did not pre-
dict the progression of MF in general (n = 65), with
appropriate sensitivity (43%) and specificity (57%)
after the exclusion of MF-3 cases on a long-term basis
(Table 1). In the short-term analysis, considering only
the initial 12 months follow-up time (n = 26), the
elevated PDGFRb score proved to be predictive of pro-
gression, with 82% sensitivity and 53% specificity
(Table 1).
Most interestingly, prefibrotic cases (initial MF-0)
showing an elevated PDGFRb score (ranging 1–2+)
turned frequently to fibrotic cases, as measured by
reticulin staining in the repeated biopsy. The progres-
sion from the prefibrotic to the fibrotic status could be
predicted with 90% sensitivity and 75% specificity
based on the initially higher PDGFR staining
(Table 1). The prefibrotic samples evaluated here
were of heterogeneous origin, including ET (two
cases), PV (two cases), PMF (six cases), CML (two
cases) and MPN-U (two cases). No other objective
clinical (gender, age, medication) or histological (bone
marrow involvement, cellularity, inflammation)
parameter potentially influencing the extent and
dynamics of the bone marrow stromal reaction could
be identified.
P R E D I C T I V E V A L U E O F P D G F R b I N S E L E C T E D
C A S E S O F P R I M A R Y M Y E L O F I B R O S I S
The group of 55 cases with a diagnosis of PMF was
the largest and most homogeneous disease group
within our multicentre study. At the time of diagno-
sis, six PMF cases proved to be prefibrotic (MF-0) and
20 cases showed MF-1, 11 cases MF-2 and 18 cases
MF-3 reticulin grade. At the same time, the PDGFRb
score was PDGFRb-0 in one case, PDGFRb-1 in 18
Table 1. Predictive value of the platelet-derived growth
factor receptor b (PDGFRb) scoring for myelofibrosis (MF)
progression
All cases
All cases within
1 year
follow-up
All prefibrotic
cases
Number of
cases
65 26 14
TP 15 9 9
TN 17 8 3
FP 13 7 1
FN 20 2 1
Sensitivity 43% (15/35) 82% (9/11) 90% (9/10)
Specificity 57% (17/30) 53% (8/15) 75% (3/4)
TP = true positive; TN = true negative; FP = false positive;
FN = false negative.
Specificity and sensitivity was calculated considering all
evaluated cases for the full length of follow-up, for the
short-term (1 year) follow-up and separately for prefibrotic
cases only. End-stage (MF-3) fibrosis was excluded, as
these cases were not subjects of further progression.
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Figure 4. Probability of progression respective to the platelet-derived growth factor receptor b (PDGFRb) score. The initially higher score did
not predict fibrosis progression in the total sample collection after the removal of MF-3 cases (A). The same result was seen when short-term
follow-up (12 months or less) was considered (B). Increase in myelofibrosis (MF) grade was defined as progression, while cases with decrease
or no change in the MF grade were considered as non-progressive.
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cases, PDGFRb-2 in 15 cases and PDGFRb-3 in 21
cases. During disease follow-up, 24 of 55 cases
(43.6%) with PMF remained unchanged, while 24
cases (43.6%) showed MF progression and seven
cases (12.8%) regression/reduction of the MF degree.
The stromal cell reaction measured by the PDGFRb
score remained unchanged in 33 of 55 cases
(60.0%), 16 showed an increase (29.1%) and six
cases (10.1%) a decrease during the total follow-up
period.
The PDGFRb score was higher than the MF grade
in 14 of 55 cases (25.5%), equal to the MF grade in
39 of 55 cases (70.9%) and lower than the MF grade
in only two of 55 cases (3.6%). Cases with a fully
developed myelofibrosis (MF-3) at the time of diagno-
sis (18 of the 55) were excluded from further evalua-
tion regarding progression. Figure 5A shows the
progression of MF in cases with higher (n = 16),
equal (n = 20) and lower (n = 1) PDGFRb scores
compared to the MF grade. There was no significant
difference in the probability of fibrosis progression in
the different subgroups (P = 0.3905). The dynamics
of PMF on a short-term basis (within 12 months’ fol-
low-up history, a total of 15 cases) was also not asso-
ciated statistically with the PDGFRb scores
(P = 0.7915), despite a prominent increase in
selected cases with progression (Figure 5B).
In PMF, a higher PDGFRb score than MF grade
predicted the progression of MF with 40% sensitivity
and 53% specificity after the exclusion of MF-3 cases
(n = 37) (Table 2). The short-term (n = 15) progres-
sion prediction was effective with 83% sensitivity and
44% specificity (Table 2). The six prefibrotic PMF
cases enrolled into this study did not allow a conclu-
sion regarding the predictive utility of PDGFRb scor-
ing.
The potential effect of the initial PDGFRb finding
on the follow-up parameters of MF was also evalu-
ated (Table 3). While the correlation between MF
grade and PDGFRb score was reproducibly strong
within the same bone marrow samples at any time
during our investigations, the initial PDGFRb score
correlated only moderately with either the MF grade
or PDGFRb score of the endpoint follow-up sample.
Discussion
Although a previous report also demonstrated PDGFR
expression in thrombopoietic cells, our earlier studies
and current observations revealed that PDGFRb
expression is limited to the endosteal and the perivas-
cular stromal niche and reticular fibroblasts in the
bone marrow.14 These differences may be explained
by the specificity of applied antibodies. PDGFRb is a
dynamically expressed and potentially targetable tyro-
sine-kinase receptor of this set of mesenchymal cell
types. The role of PDGFR signalling has been studied
extensively experimentally15 and its role could be
demonstrated in fibrotic disorders, such as in local
and systemic sclerosis and in neoplasias of mesenchy-
mal origin.16–19 The increased amounts of PDGFRb-
expressing fibroblasts also proved to be a characteris-
tic feature of the different degrees of myelofibrosis.
Using PDGFRb immunohistochemistry, the topogra-
phy and dynamics of the newly generated fibroblasts
can be followed in the diseased bone marrow.
Although the link between receptor expression and
matrix fibre synthesis is not completely clear, the
total amount of the PDGFRb immunopositivity was
associated strongly with reticulin fibre deposition,
which could also be reproduced by the present study.
According to current opinion, the degree of MF is an
important clinical parameter reflecting disease activ-
ity. The amount and distribution of reticulin and col-
lagen fibres, however, is a result of the activity and
proliferation of stromal fibroblasts. For this reason,
we speculated that the cellular activation marker
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Figure 5. Probability of progression in primary myelofibrosis (PMF) reflected by the platelet-derived growth factor receptor b (PDGFRb) score.
The initially higher score did not predict progression of fibrosis during the full-length (A) or short-term (B) follow-ups. Initial MF-3 cases
were excluded as these were not subjects of further progression.
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PDGFRb might be useful to highlight ongoing cellular
processes occurring in association with or even in
advance of stromal fibre deposition.
Using a microscopic scoring system, detailed evalu-
ation of 193 bone marrow samples from five Euro-
pean centres clearly validated the close relationship
between the conventionally determined MF grade and
the fibroblast activation marker PDGFRb. Moreover,
elevated PDGFRb scores indicated stromal activity in
a significant portion of the samples, also disclosing
early lesions lacking prominent reticulin fibrosis.
According to our evolving concept, fibroblast activa-
tion may also reflect early phases of stromal reaction,
the result of which can only be identified in subse-
quent bone marrow samples as clinically relevant
fibrosis. In our comparison, however, no strong pre-
dictive role could be stated for the actual PDGFRb
status in myeloproliferative disease – even if the fol-
low-up period was limited to only 1 year. Conversely,
patients at risk for progressive bone marrow disease
could be identified with a sensitivity of 90% and spec-
ificity of 75% among cases presenting initially with
MF-0 (prefibrotic) if the PDGFRb score was elevated
(Table 1). Unfortunately, the low number of cases did
not allow us to reproduce the same predictive effect
when PMF was evaluated separately (six prefibrotic/
55 PMF cases).
According to current opinion, MF is itself an
accompanying condition appearing with variable
dynamics in myeloproliferative disease. The course of
myelofibrosis is influenced by many factors, and the
appreciation of MF progression is difficult and some-
what limited. Early fibrosis may occur in different
degrees throughout the bone marrow, frequently with
only focal presentation in biopsy samples. In particu-
lar, the MF-2 grade may be associated with signifi-
cant heterogeneity and a broad spectrum in
parenchymal reticulin accumulation, making a sin-
gle-parameter histological evaluation and statistical
consideration problematic. The dynamics of fibrosis in
bone marrow disease are also reliant upon the local
cytokine/growth factor stimuli depending on the com-
position of the neoplastic microenvironment. Con-
versely, the fibre production may be affected
significantly by the treatment applied. Due to this
complexity, fibroblast activation and extracellular
fibre accumulation represent two different biological
aspects of the same pathological process. As a major
finding of our study, we validated the generally
strong linear association between bone marrow fibro-
sis and PDGFRb-expressing mesenchymal cells. Fur-
ther, the elevated PDGFRb expression in initial
prefibrotic bone marrow lesions indicated progression
in the absence of fibre deposition. According to our
concept, up-regulation of the PDGF receptor for opti-
mal ligand binding is required very early in advance
of significant stromal proliferation and matrix produc-
tion, a feature that can be demonstrated uniformly in
parallel with the neoplastic transformation of the
bone marrow. Thus, increased PDGFRb expression
can be expected in all phases and even before mani-
fest myelofibrosis (MF-0). Finally, the fibrotic process
Table 2. Specificity and sensitivity of the elevated platelet-
derived growth factor receptor b (PDGFRb) score to predict
progression in primary myelofibrosis (PMF)
PMF cases
PMF cases
within 1 year
follow-up
Prefibrotic
PMF cases
Number of
cases
37 15 6
TP 8 5 4
TN 9 4 0
FP 8 5 1
FN 12 1 1
Sensitivity 40% (8/20) 83% (5/6) (4/5)
Specificity 53% (9/17) 44% (4/9) (0/1)
TP = true positive; TN = true negative; FP = false positive;
FN = false negative.
Initially, MF-3 cases were excluded, as these were not sub-
jects of further progression. Analysis was performed for all
PMF cases within the full follow-up range and also for
cases having short-term follow-up. Prefibrotic PMF could
not be evaluated separately due to low case number
(n = 6).
Table 3. Correlation of the initial platelet-derived growth
factor receptor b (PDGFRb) score with the follow-up status
in primary myelofibrosis (PMF); PDGFRb score correlated
well with the MF grade of the same sample, but regression
coefficients did not support a strong relation with the end-
point bone marrow status
Correlations with initial beta score
(n = 55)
MF initial MF endpoint
Beta
endpoint
Spearman’s r 0.8463 0.4002 0.4931
P-value
(two-tailed)
<0.0001 0.0025 0.0001
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may be gradually tuned down due to the loss of para-
crine stimuli in end-stage fibrotic bone marrow dis-
ease (MF-3). For these reasons, the use of stromal
activation markers, together with the classical disease
characteristics, offers a completely new insight into
the pathological processes against a background of
ongoing stromal fibrosis. In clinical practice, PDGFRb
IHC provides valuable additional information when
the reticulin staining is difficult to interpret or when
immunostainings are preferred to classical histochem-
istry. Interpretation of the staining pattern requires
only minimun effort and the proposed scoring is eas-
ily comparable with the reticulin-based grading.
In the current study we focused on the pathologi-
cal progression of MF as an endpoint of our investiga-
tions, which covered mainly histological parameters.
Clinical correlations regarding the PDGFR expression
similar to the reticulin MF grade are highly difficult
to measure due to the heterogeneous nature and the
different, individually adapted clinical management of
the myeloproliferative neoplasias. Probably for the
same reasons, despite a consistent correlation within
the same sample, an association between the initial
and endpoint MF grade or PDGFR score could not be
demonstrated (Table 3).
In summary, despite the above-mentioned biological–
histological variables, PDGFRb immunohistochemistry
proved to be a robust indicator of marrow stromal reac-
tion that could be measured reproducibly in bone mar-
row biopsies. PDGFRb highlights the cellular aspects of
fibrosis that are related closely to the reticulin and col-
lagen accumulation. Its potential value to predict pro-
gression in early, prefibrotic myeloproliferative
neoplasias could also be demonstrated based on a small
number of retrospective follow-up cases which, how-
ever, calls for validation in a larger sample collection.
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